Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pemetrexed combined with lenalidomide for relapsed or refractory primary central nervous system lymphoma
ChiCTR1900028070Phase 2Recruiting
- Sponsor
- Huashan Hospital North, Fudan University
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and lenalidomide in primary central nervous system lymphoma (PCNSL), sponsored by Huashan Hospital North, Fudan University. Primary endpoint: Complete remission rate. Started Jun 2018; status: recruiting.
02
Drugs
pemetrexedlenalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR1900028070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028070.